Sep 12, 2022 / 01:55PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley.
Really pleased to have Biogen with us for the next session. We have Michael McDonnell, who's the CFO and Chris who is the Interim Head of R&D. Michael, I know you want to make some opening comments, I'll turn it over to you, and then we can jump into it.
Michael R. McDonnell - Biogen Inc. - Executive VP & CFO
Sure. Thank you, Matthew, and thanks for having us. Thanks for joining us, everyone. I do want to mention upfront that Priya and I may be making some forward-looking statements during the course of the presentation this morning, which have certain risks and uncertainties, and I would refer you to our risk factors in our public filings as actual outcomes could be different than forward-looking statements.
So at Biogen, it's been a few months now since we last reported. July was the last time we reported our
Biogen Inc at Morgan Stanley Global Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers